Synlian Linaprazan Glurate Capsules

1. Indications and Usage
Gastroesophageal Reflux Disease (GERD): Treatment of gastroesophageal reflux disease in adults, including the healing of erosive esophagitis and management of related symptoms such as heartburn and regurgitation.
2. Dosage and Administration
Route of Administration: Oral administration ONLY.
Standard Dosage: 15 mg (one capsule) once daily.
Dosage Adjustment: In patients with severe hepatic impairment, the dosage should be reduced to 5 mg once daily.
Critical Administration Instructions:
Meal Timing: Administration is not dependent on meals; it can be taken with or without food.
Swallowing: Capsules should be swallowed whole and must not be chewed or crushed.
3. Mechanism of Action
Potassium-Competitive Acid Blockade: Linaprazan is a P-CAB that competitively and reversibly blocks the K⁺/H⁺-ATPase (proton pump) on the gastric parietal cell membrane.
Rapid Onset: Unlike traditional proton pump inhibitors (PPIs), linaprazan does not require acid-dependent activation and maintains stable plasma concentrations, providing rapid and sustained acid suppression from the first dose.
4. Safety and Warnings
Hypomagnesemia: Long-term use may lead to decreased serum magnesium levels, which can cause serious adverse events such as arrhythmias, seizures, and tetany.
Infection Risk: Suppression of gastric acidity increases the risk of gastrointestinal infections, including Clostridioides difficile and other enteric infections.
Vitamin B12 Deficiency: Long-term use may impair vitamin B12 absorption; periodic monitoring is recommended for patients on extended therapy.
Renal and Hepatic Impairment: Use with caution in patients with severe renal or hepatic dysfunction due to altered drug metabolism and clearance.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Diarrhea, headache, abdominal pain, nausea, and increased blood creatinine.
Clinical Research Highlights: Clinical trials have demonstrated that linaprazan provides superior acid suppression compared to traditional PPIs, with faster healing rates for erosive esophagitis and effective symptom relief in GERD patients.
6. Drug Interactions
Atazanavir and Nelfinavir: Linaprazan significantly increases gastric pH, which reduces the dissolution and bioavailability of these HIV protease inhibitors; concomitant use is not recommended.
Methotrexate: P-CABs may increase serum methotrexate levels, potentially leading to toxicity; monitoring or dose adjustment is advised.
Drugs Dependent on Gastric Acidity: Concomitant use with drugs that require an acidic environment for absorption (e.g., ketoconazole, itraconazole, iron salts) may reduce their therapeutic efficacy.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Linaprazan Glurate.
Appearance: Gelatin capsules with a colored cap and body, containing powder or granules.
Packaging: Available in blister packs (e.g., 15 mg strength).
Storage: Store at controlled room temperature in a well-closed container, protected from light and moisture.